2- amino- 6- (4- methoxyphenylthio)- 9- (2- (phosphonomethoxy)ethyl)purine bis(2,2,2-trifluoroethyl) ester

an HBV-specific antiviral agent; structure in first source

Also Known As:

2-amino-6-(4-C(11)-methoxyphenylthio)-9-(2-(phosphonomethoxy)ethyl)purine bis(2,2,2-trifluoroethyl); MCC 478; MCC-478; MCC478; alamifovir

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Lowe, Stephen L: 1 article (11/2004)
2.	McGill, James: 1 article (11/2004)
3.	Soon, Danny K W: 1 article (11/2004)
4.	Teng, Choo Hua: 1 article (11/2004)
5.	Wise, Stephen D: 1 article (11/2004)
6.	Yeo, Kwee Poo: 1 article (11/2004)
7.	Carrilho, Flair José: 1 article (08/2002)
8.	Kato, Naoya: 1 article (08/2002)
9.	Omata, Masao: 1 article (08/2002)
10.	Ono-Nita, Suzane Kioko: 1 article (08/2002)

1.	Chronic Hepatitis B 11/01/2004 - "Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection." 11/01/2004 - "A randomised, placebo controlled, dose escalation study of oral alamifovir was conducted in 66 chronic hepatitis B infected patients who were selected based on stable HBV DNA (>10(5)copies/ml), with no significant liver pathology. "
2.	Infections 08/01/2002 - "MCC-478 appears to be a candidate for the treatment of HBV infection and exhibits potent activity against lamivudine-resistant HBV."
3.	Hepatocellular Carcinoma (Hepatoma) 08/01/2002 - "The susceptibility of wild-type HBV and lamivudine-resistant mutants (M552I, M552V, and L528M/M552V) to MCC-478 was examined by transient transfection of full-length HBV DNA into human hepatoma cells. "